0000950170-24-071539.txt : 20240610 0000950170-24-071539.hdr.sgml : 20240610 20240610194301 ACCESSION NUMBER: 0000950170-24-071539 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240606 FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bredt David CENTRAL INDEX KEY: 0002022087 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42121 FILM NUMBER: 241034340 MAIL ADDRESS: STREET 1: C/O RAPPORT THERAPEUTICS STREET 2: 1325 BOYLSTON ST., SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rapport Therapeutics, Inc. CENTRAL INDEX KEY: 0002012593 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880724208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: 857-321-8020 MAIL ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 4 1 ownership.xml 4 X0508 4 2024-06-06 0002012593 Rapport Therapeutics, Inc. RAPP 0002022087 Bredt David RAPPORT THERAPEUTICS, INC. 1325 BOYLSTON STREET, SUITE 401 BOSTON MA 02215 false true false false Chief Scientific Officer false Stock Option (Right to Buy) 17 2024-06-06 4 A false 28302 0.00 A 2034-06-05 Common Stock 28302 28302 D 25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. /s/ Cheryl Gault, Attorney-in-Fact 2024-06-10